Current Report Filing (8-k)
March 07 2017 - 3:20PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
_____
March 1, 2017
______
NORTHWEST BIOTHERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-35737
|
94-3306718
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
4800 Montgomery Lane, Suite 800
Bethesda, MD 20814
|
(Address of principal executive offices)
|
(204) 497-9024
|
(Registrant’s telephone number, including area code)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the
Securities Act
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 1.01.
|
Entry into a Material Definitive Agreement.
|
Commencing March 1,
2017, Northwest Biotherapeutics, Inc. (the “Company”) entered into a series of six nonconvertible, promissory notes
with unrelated third parties (the “Notes”) in the original principal amount of $2,020,000 with an original issuance
discount of 3% for aggregate net proceeds of $1,959,400 without interest. The Notes have a six-month maturity, may be prepaid without
penalty by the Company prior to maturity and the lenders maintain an option to require payment prior to maturity upon the Company’s
raising a minimum of $15 million. On March 3, 2017, the Company entered into an additional nonconvertible, promissory note with
an unrelated third party in the original principal amount of $1,155,000 with an original issuance discount of 10% for aggregate
net proceeds of $1,000,000 with interest at 8% per annum. Such note has a six-month maturity, may be prepaid without penalty by
the Company prior to maturity and the lender maintains an option to require payment prior to maturity upon the Company’s
raising a minimum of $5 million.
Item 2.03
|
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
|
The information contained above in Item
1.01 is hereby incorporated by reference into this Item 2.03.
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE
SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO
DULY AUTHORIZED.
|
NORTHWEST BIOTHERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
|
Date: March 7, 2017
|
By:
|
/s/
Linda F. Powers
|
|
|
Name: Linda F. Powers
Title: Chief Executive Officer
|
|
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Sep 2023 to Sep 2024